BIA 28-6156-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Gluc

Grants and Contracts Details

StatusActive
Effective start/end date10/9/2310/9/25

Funding

  • Worldwide Clinical Trials: $36,282.00